HC-7366
HC-7366 is our differentiated, first-in-human therapeutic candidate designed to activate the General Control Nonderepressible 2 (GCN2) kinase. GCN2 is critical to the function of the Integrated Stress Response (ISR) signaling pathway.
Targeting the Integrated Stress Response in Cancer
Treatment resistance, cancer relapse, and metastasis are too often the unfortunate outcome for cancer patients. We have evidence that a common feature of tumors that resist treatment, relapse, and metastasize is reliance on adaptive stress pathways such as the integrated stress response (ISR). We are pioneering the development of differentiated treatment approaches that target the ISR to help patients live longer, cancer-free lives.
Targeting the Integrated Stress Response in Cancer
Treatment resistance, cancer relapse, and metastasis are too often the unfortunate outcome for cancer patients. We have evidence that a common feature of tumors that resist treatment, relapse, and metastasize is reliance on adaptive stress pathways such as the integrated stress response (ISR). We are pioneering the development of differentiated treatment approaches that target the ISR to help patients live longer, cancer-free lives.
Targeting the Integrated Stress Response in Cancer
Treatment resistance, cancer relapse, and metastasis are too often the unfortunate outcome for cancer patients. We have evidence that a common feature of tumors that resist treatment, relapse, and metastasize is reliance on adaptive stress pathways such as the integrated stress response (ISR). We are pioneering the development of differentiated treatment approaches that target the ISR to help patients live longer, cancer-free lives.
Working to Exploit Stress Driven Vulnerabilities in Cancer Cells
Despite clinical improvements made with the use of approved precision therapies and therapeutic candidates, cancer cells leverage adaptive stress pathways such as the integrated stress response to adapt, survive, and become resistant to treatment. However, stress also causes cells to be more vulnerable to alternative therapeutic approaches. We believe that we can work to exploit these vulnerabilities through the following approaches:
- Inhibit stress-mitigating pathways (HC-5404): Prevent cancer cell survival and adaptation by inhibiting stress-mitigation pathways
- Increase stress signaling (HC-7366): Overwhelm stress-mitigation pathways and induce apoptosis (cell death) by hyperactivation
Experienced Leadership Team
Our team is led by experienced biotech executives committed to the clinical development of our first-in-human therapeutic candidates. Our team embodies the values of scientific rigor and urgency, which are important to our mission of developing therapeutics that improve the lives of patients.
News & Events
11.04.25 - news
AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
05.27.25 - news
HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC
04.28.25 - news
HiberCell’s Board of Directors Appoints Steven Gillis, Ph.D., the Company’s Current Chairman of the Board, as Chairman and Acting CEO
04.14.26 - news
HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)
11.04.25 - news